Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
Provided By GlobeNewswire
Last update: Sep 23, 2024
BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed
Preliminary ORR of 42% in 19 patients at 200 mg with on-target resistance EGFR mutations
Read more at globenewswire.com
